Alliance for Pandemic Preparedness

June 12, 2020

Early Administration of Lopinavir/ritonavir plus Hydroxychloroquine Does Not Alter the Clinical Course of SARS-CoV-2 Infection a Retrospective Cohort Study

Category:

Topic:

  • [pre-print, not peer reviewed] Giacomelli et al. studied early (<5 days from onset of symptoms, n=43) vs. delayed (n=129) initiation of lopinavir/ritonavir and hydroxychloroquine (LPV/r + HCQ) on clinical outcomes by analyzing a cohort of patients with COVID-19. All patients meeting the eligibility criteria were offered LPV/r + HCQ. After adjusting for clinical factors, the odds ratio (OR) for 30–day mortality was 1.45 (95%CI 0.50, 4.19). Increase in hepatic enzymes, nausea, and diarrhea were the most common adverse events. 

Giacomelli et al. (June 12, 2020). Early Administration of Lopinavir/ritonavir plus Hydroxychloroquine Does Not Alter the Clinical Course of SARS-CoV-2 Infection a Retrospective Cohort Study. Pre-print downloaded June 12 from https://doi.org/10.1101/2020.06.05.20123299